Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Investor Presentation (February 2019)
29 slides from Jubilant Pharmova's investor presentation, February 2019
Slide 1: Jubilant Life Sciences Limited Investor Presentation
Jubilant Life Sciences Limited Investor Presentation February 2019
Slide 2: Important Disclaimer
Disclaimer Important Disclaimer This presentation (the “Presentation”, or the “document”) has been prepared by Jubilant Life Sciences Limited (the “Company”) for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for
Slide 3: Jubilant Life Sciences Overview
Jubilant Life Sciences Overview Pharmaceuticals Life Science Ingredients Specialty Pharmaceuticals Radiopharmaceuticals Specialty Intermediates and Nutritional Others Allergy Therapy Products Products Drug Discovery CDMO Solutions CMO of Sterile Injectables and Non Sterile Products India B
Slide 4: Pharmaceuticals Segment
f) we > Vie 6 —_—, wW jupiaAnt Pharmaceuticals Segment LIFESCIENCES
Slide 5: Evolution of Jubilant Pharma
Evolution of Jubilant Pharma Revenue Split(1) JLL acquired Acquired a majority stake in Acquired Draxis Pharma SGX-listed high Completed FY18 API business – Cadista Holdings Inc. Inc. in Canada yield bond acquisition of US$619mm Nanjangud, (generics pharmaceutical (manufacturer of sterile offering T
Slide 6: Radiopharmaceuticals Business
Radiopharmaceuticals Business Market Size of Industry in North America 3.5 Radiopharmaceuticals Industry in North America is US$2.4bn, expected to grow at CAGR of 6.2% to reach 2.9 3.0 3.2 2.6 2.7 2.2 2.3 2.4 US$3.5bn by 2023 1.9 2.0 Industry (US$bn) Overview (1) Oncology and cardiology diagnosi
Slide 7: Radiopharmacy Business
Radiopharmacy Business # 2 commercial radiopharmacy network in the US, operated under the “Triad Isotope” brand Facilities also include three operational cyclotrons Multi-year agreements with GPOs in place 52 radiopharmacies spread across 22 states 750+ employees c.3 mn+ doses delivered annual
Slide 8: Allergy Therapy Business
Allergy Therapy Business Allergen Immunotherapy (AIT) Market Size Global AIT market stands at US$1.8bn and is expected to grow at CAGR of 8.9% to reach US$2.8bn by 2022 2.6 2.8 2.3 0.5 2.1 0.4 Major growth drivers include the increased prevalence of allergic diseases, reduced time to drug 1.7 1.
Slide 9: Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products
Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products Global Pharmaceutical CMO Industry Size 125 134 100 109 117 5 5 7 Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a 92 5 6 7 12 12 79 85 4 5 6 11 73 4 6 11 Industry 59
Slide 10: API Business
API Business Global Market Size : Synthetic API 149 123 131 129 Global Synthetic API market is US$115bn in 2018 and is expected to grow at a 115 Industry 46 62 51 53 CAGR of 6.7% from 2018 to 2022F to reach US$149bn(1) (US$bn) 48 Overview 53% of outsourced API market is generics(1) 67 72 78 83 8
Slide 11: Solid Dosage Formulations Business
Solid Dosage Formulations Business Global Generics Pharmaceuticals Industry Size by Unbranded Generic Global generics pharmaceutical industry stands at US$111bn Sales(3) US Patent Expiry for Small Molecules and is expected to grow at CAGR of 5.2% to reach US$136bn US$ 72.5 bn by 2023 136 117 123 1
Slide 12: Life Science Ingredients Segment
Life Science Ingredients Segment 12
Slide 13: Specialty Intermediates & Nutritional Products
Specialty Intermediates & Nutritional Products Global Market Size ($ Mn) : Speciality Chemicals Global Market Size (KT): Vitamin B3 Global specialty chemicals market is USD 1.1 billion in 2018 and is expected to grow at 5.4% to reach USD 1.2 Industry billion in 2022. Overview Global nutrition ma
Slide 14: Life Science Chemicals
Life Science Chemicals Global Market Size (KT): Acetic Global Market Size (KT): Ethyl Anhydride Acetate Global Acetic Anhydride market is 585 KT in 2018 and is expected to Industry grow at 4.2% to reach 662KT in 2022 Overview Global Ethyl Acetate market is 2046 KT in 2018 and is expected to grow
Slide 15: Jubilant Life Sciences – Key Strengths & Strategies
Jubilant Life Sciences – Key Strengths & Strategies 15
Slide 16: Jubilant Life Sciences Key Strengths
Jubilant Life Sciences Key Strengths 1 Strong Leadership in Key Products and Markets 2 Global Competitive Edge Due to Low Cost and Vertical Integration 3 De-risked Business Model With Diverse Sources of Revenue 4 Strong Pipeline of Products with Deep R&D Capabilities 5 High-Quality, World –Class, Lo
Slide 17: Leading Market Positions Across Business Lines, High Barriers To Entry
Leading Market Positions Across Business Lines, with High Barriers To 1 Entry For Specialty Pharmaceuticals Highlights Entry Barriers #3 radiopharmaceuticals manufacturer in the US (1)(2) Extensive regulatory and licensing requirements #2 commercial radiopharmacy network in the US (1) (3) Spec
Slide 18: Global Competitive Edge Due to Low Cost and Vertical Integration
Global Competitive Edge Due to Low Cost and Vertical 2 Integration Vertical integration across the value chain enables cost competitive advantage resulting in higher margins Integrated Operations… Life Sciences Ingredients 4 5 6 7 Radiopharmacies Crop Animal & Provides direct access to Fine Scienc
Slide 19: De-risked Business Model With Diverse Sources of Revenue
3 De-risked Business Model With Diverse Sources of Revenue Presence in niche Specialty businesses that have high barriers to entry Diverse end-use industry segmentation in Life Science Ingredients with focus on Pharmaceutical and Agrochemical industries Presence across geographic locations ena
Slide 20: Strong Pipeline of Products With Deep R&D Capabilities
4 Strong Pipeline of Products With Deep R&D Capabilities Strong R&D capabilities demonstrated by complex and niche product filings including 505(b)(2) in radiopharma Strong R&D support with a dedicated workforce of more than 500 R&D professionals 39 commercial APIs, 94 US DMFs filed Pharmaceut
Slide 21: High-Quality, World-Class, Low Cost Manufacturing Footprint
5 High-Quality, World-Class, Low Cost Manufacturing Footprint Spokane, Washington, USA Roorkee, Uttarakhand Contract manufacturing of Sterile Generics manufacturing injectable and Allergy therapy Gajraula, Uttar Pradesh Largest integrated facility of Specialty Intermediates and Samlaya, Gujara
Slide 22: Experienced Management Team with High Standards of Corporate Governance
Experienced Management team with high standards of corporate 6 governance Shyam S Bhartia Hari S Bhartia Chairman Co-Chairman & Managing Director 39 industry years in pharma, specialty 33 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foods, oil and ga
Slide 23: Demonstrated Financial Track Record with Strong Revenue Growth
Demonstrated Financial Track Record with Strong Revenue Growth and 7 Attractive Profitability Profile Revenue from Operations Total Revenue EBITDA Split Reported EBITDA1 Revenue increased at a CAGR 5,826 5,893 5,861 7,518 5,266 6,725 732 1,291 1,370 1,558 1,078 1,423 of 9.1% over FY16-18 and EBITD
Slide 24: Growth Strategies and Plans
Growth Strategies and Plans Continue to strengthen leadership positions in key business segments 1 Radiopharmaceuticals: Achieve market leadership by leveraging leadership in existing products and expanding our product portfolio through the launch of niche and differentiated products CMO: Streng
Slide 25: Growth Strategies and Plans
Growth Strategies and Plans 3 Develop a diverse product and service portfolio through differentiated and complex offerings Specialty Pharmaceuticals Focus: Develop differentiated products in the radiopharmaceuticals and specialty injectables segments catering to the North American market Generic
Slide 26: Appendix
Appendix W JUBILANT LIFESCIENCES
Slide 27: Jubilant Life Science Q3/9M'FY19 – Financial Snapshot
Jubilant Life Science Q3/9M’FY19 – Financial Snapshot Particulars Q3 FY 18 Q3 FY19 YoY Growth 9M FY18 9M FY 19 YoY Growth (Rs Crs) (%) (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 2068 2377 15% 5266 6725 28% Pharmaceuticals 1096 1418 29% 2762 3925 42% Specialty Pharmaceuticals 612 757
Slide 28: Debt Profile
Debt Profile Particulars 31/03/18 31/12/18 Foreign Currency Loans ($ Mn) ($ Mn) Standalone 9 0 Subsidiaries 358 356 Total 367 356 Rupee Loans (Rs. Crs) (Rs. Crs) Standalone 1,007 1,252 Subsidiaries 79 61 Total 1,086 1,313 Gross Debt (Rs. Crs) (Rs. Crs) Standalone 1,066 1,252 Subsidiaries 2,414 2,548
Slide 29: Our Vision & Promise
Our Vision & Promise Visit Us: Web Site: www.jubl.com Jubilant Life Sciences Limited, 1-A, Sector 16-A, NOIDA- 201301 UP, India For Investors: Ravi Agrawal Vineet V Mayer Ph: +91-120-436 1002 Ph: +91-120-436 1021 E-mail: ravi.agrawal@jubl.com E-mail: Vineet.mayer@jubl.com 29
Jubilant Life Sciences — Investor Presentation (February 2019) on 6ix